Skip to main content
SpringerLink
Log in

Biología Molecular de los cánceres de cabeza y cuello

Molecular Biology in head and neck cancer

  • Revisiones
  • Published:
Revista de Oncología Aims and scope Submit manuscript

Resumen

Se ha visto que los cánceres de cabeza y cuello tienen múltiples anomalías genéticas que influyen en el desarrollo y comportamiento del tumor y pueden ser útiles para la creación de nuevas terapias.

En este trabajo se describen una serie de anomalías citogenéticas y moleculares relacionadas con la susceptibilidad, cancerización y pronóstico de los tumores de cabeza y cuello.

Esta revisión expondrá algunos avances en el tratamiento de pacientes con cáncer de cabeza y cuello; enfatizando en la forma en la que la Biología Molecular probablemente influya en el desarrollo de futuras terapias.

Abstract

Head and neck cancers have multiple genetic abnormalities that influence tumor behavior and may be useful in developing new therapies.

This review presents a large number of cytogenic and molecular abnormalities involved in head and neck cancer susceptibility, field cancerization, and prognosis.

This review will highlight some important advances in the treatment of patients with head and neck cancer and emphasize the ways in which Molecular Biology is likely to affect the development of future therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Bibliografía

  1. Cloos J, Braakhuis BJ, Snow GB, et al. Assesment of genetic susceptibility as a risk factor for head and neck squamous cell carcinoma. Otolaryngol Pol 1997;5:127–32.

    Google Scholar 

  2. Cheng L, Eicher SA, Guo Z, et al. Reduced DNA repair capacity in head and neck cancer patients. Cancer Epidemiol Biomarkers Prev 1998;7:465–8.

    CAS  PubMed  Google Scholar 

  3. Wei Q, Xu X, Cheng L, et al. Simultaneous amplification of four repair genes and beta-actin in human lymphocytes by multiple reverse transcriptase-PCR. Cancer Res 1995;55:5025–9.

    CAS  PubMed  Google Scholar 

  4. Cheng L, Sturgis GM, Eicher SA, et al. Expression of nucleotide excision repair genes and the risk for squamous cell carcinoma of the head and neck. Cancer 2002;94:393–7.

    Article  CAS  Google Scholar 

  5. Lazarus P, Park JY. Metabolizing enzyme genotype and risk for upper aerodigestive tract cancer. Oral Oncol 2000;36:421–31.

    Article  CAS  Google Scholar 

  6. Ophius MB, Van Lieshout EMM, Roelofs HMJ, et al. Glutation S transferase M1 and T1 and cytocrome P450A1 polymorphisms in relation to the risk of benign and malignant head and neck lesions. Cancer 1998;82:936–43.

    Article  Google Scholar 

  7. Jourenkova-Mirinova N, Voho A, Bouchardy B, et al. Gluthatione S transferase GSTM1, GSTM3, GSTP1 genotypes and the risk of smoking related oral and faryngeal cancers. Int J Cancer 1999;81:44–8.

    Article  Google Scholar 

  8. Gonzales MV, Alvarez V, Pello MF, et al. Genetic polymorphism of N-acetyltransferase-2, glutathione S transferase M1 and cytochromes P450 IIE1 and cytochrome IID6 in the susceptibility to head and neck cancer. Clin Pathol 1998;51:294–8.

    Article  Google Scholar 

  9. Fronhoffs S, Brunning T, Ortiz Pallardo E, et al. Real time PCR analysis of the N-acetyl transferase NAT-1 allele 3, 4, 10, 11, 14 and 17 polymorphism in squamous cell carcinoma of the head and neck. Carcinogenesis 2001;22:1405–12.

    Article  CAS  Google Scholar 

  10. Schuckit MA. New findings in the genetics of alcoholism. J Am Med Assoc 1999;20:1875–6.

    Article  Google Scholar 

  11. Guillison ML, Koch WM, Sppaford M, et al. Causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000;92:709–20.

    Article  Google Scholar 

  12. Viola MM. Biological evidence that human papillomavirus are etiologically involved a subgroup of head and neck squamous cell carcinomas. Int J Cancer 2001;93:2323–5.

    Google Scholar 

  13. Almadori G, Cadoni G, Cattani P, et al. Human papillomavirus infection and epidermal growth factor receptor expression in primary laryngeal squamous cell carcinoma. Clin Cancer Res 2001;7:3988–93.

    CAS  PubMed  Google Scholar 

  14. Beck A, Päzol D, Grabebauer G, et al. Expression of cytokine and chemokine genes in Epstein Barr virus associated nasopharyngeal carcinoma: comparison with Hodgkin's disease. J Pathol 2001;194:145–51.

    Article  CAS  Google Scholar 

  15. Khanna R, Busson P, Burrows SR, et al. Molecular characterization of antigen processing function in nasopharyngeal carcinoma: evidence for efficient presentation of Ebstein Barr virus citotoxic T-cell epitopes by NCP cells. Cancer Res 1998;58:310–4.

    CAS  PubMed  Google Scholar 

  16. Bedi GC, Westra WH, Gabrielson E, et al. Multiple head and neck tumors: evidence for a common clonal origin. Cancer Res 1996;56:2484–7.

    Google Scholar 

  17. Slaugter DL, Southwich HW, Smejkal W. “Field cancerization” in oral stratified squamous epithelium: clinical implications of multicentric origin. Cancer 1973;6:963–8.

    Article  Google Scholar 

  18. Tabor NP, Brakenhoff RH, van Honten VM, et al. Persistence of genetically altered fields in head and neck cancer patients: biology and clinical implications. Clin Cancer Res 2001;7:1523–32.

    CAS  PubMed  Google Scholar 

  19. Leong PP, Rezai B, Koch WM, et al. Distinguishing second primary tumor and metastases in patients with head and neck squamous cell carcinoma. J Natl Cancer Inst 1998;90:972–9.

    Article  CAS  Google Scholar 

  20. Van Dike DL, Worsham MJ, Benninger MS, et al. Recurrent cytogenetic abnormalities in squamous cell carcinoma of the head and neck region. Genes Chrom Cancer 1994;9:192–201.

    Article  Google Scholar 

  21. Jin Y, Mertens F, Mandal N, et al. Chromosome abnormalities in eight-three head and neck squamous cell carcinomas: influence of culture conditions of karyotypic pattern. Cancer Res 1993;53:2140–5.

    CAS  PubMed  Google Scholar 

  22. Van der Riet P, Nawrot H, Hurban RH, et al. Frequent loss of 9p21-22 early in head and neck cancer progression. Cancer Res 1994;54:1156–8.

    PubMed  Google Scholar 

  23. Cairns P, Polascitk TJ, Eby H, et al. Frequency of homozygous delection of p16/CDKN2 in primary human tumors. Nat Genet 1995;11:210–2.

    Article  CAS  Google Scholar 

  24. Cowan JM, Beckett MA, Weichselbaum RR, et al. Chromosome changes caracterizingin vitro response to radiation in human squamous cell carcinoma lines. Cancer Res 1993;53:5542–51.

    CAS  PubMed  Google Scholar 

  25. Brozska PM, Levin NA, Fuk KK, et al. Frequent novel DNA copy number increase in squamous cell head and neck tumors. Cancer Res 1995;55:3055–63.

    Google Scholar 

  26. Rowley H. The molecular genetics of head and neck cancer. Laryngol Otol 1998;112:607–12.

    Article  CAS  Google Scholar 

  27. Brennan JA, Mao I, Hruban R, et al. Molecular assessment of histhopathological staging in squamous cell carcinoma of the head and neck. N Engl J Med 1995;332:429–35.

    Article  CAS  Google Scholar 

  28. Gleich LL, Salamone FN. Molecular genetics of head and neck cancer. Cancer Control 2002;9:369–78.

    Article  Google Scholar 

  29. Akervall JA, Michalides RJ, Mineta H, et al. Amplification of cyclin D1 in squamous cell carcinoma of the head and neck and the prognostic value of chromosomes abnormalities and Cycline D1 overexpression. Cancer 1997;79:380–9.

    Article  CAS  Google Scholar 

  30. Nakahara Y, Shintani S, Mihahara M, et al. Alterations of Rb, p16 (INK4A) and cyclin D1 in the tumorogenesis of oral squamous cell carcinomas. Cancer Lett 2000;160:3–8.

    Article  CAS  Google Scholar 

  31. Bova RJ, Quinn DI, Nankervis JS, et al. Cyclin D1 and p16 (INK4A) expression predict reduced survival in carcinoma of the anterior tongue. Clin Cancer Res 1999;5:2810–9.

    CAS  PubMed  Google Scholar 

  32. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993;366:704–7.

    Article  CAS  Google Scholar 

  33. Vielba R, Bilbao J, Ispizua A, et al. P53 and cyclin D1 as prognostic factors in squamous cell carcinoma of larynx. Laryngoscope 2003;113:167–72.

    Article  CAS  Google Scholar 

  34. Michalides RJ, van Veelen NM, Kristel PM, et al. An overexpression of cyclin D1 indicates poor prognosis in squamous cell carcinoma of head and neck. Arch Otolaryngol Head Neck Surg 1997;123:497–502.

    Article  CAS  Google Scholar 

  35. Namazie A, Alavi S, Olopade OI, et al. Cyclin D1 amplification and p16 (MST1/CDK41) deletion correlate with poor prognosis in head and neck tumors. Laryngoscope 2002;112:472–81.

    Article  CAS  Google Scholar 

  36. Derynck R. The physiology of transforming growth factor-alpha. Adv Cancer Res 1992;58:27–52.

    Article  CAS  Google Scholar 

  37. Santini J, Formento JL, Francoual M, et al. Characterization, quantification and potential clinical value of the epidermial growth factor receptor in head and neck squamous cell carcinomas. Head Neck 1991;13:132–9.

    Article  CAS  Google Scholar 

  38. Sorrells DL, Ghali GE, Metchonat C, et al. Competitive PCR to detect eIf4e gene amplification in head and neck cancer. Head Neck 1999;21:60–9.

    Article  CAS  Google Scholar 

  39. Sorrells DL, Metchonat C, Black D, et al. Pattern of amplification and overexpression of the eucaryotic initiation factor 4E gene in solid tumor. J Surg Res 1999;85:37–41.

    Article  CAS  Google Scholar 

  40. Dasonville O, Formento JL, Francoual M, et al. Expresión on epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol 1993;11:1873–8.

    Article  Google Scholar 

  41. Wen KH, Miwa T, Yoshizaki T, et al. Prognostic value of EGFR and TNF alpha in early laryngeal cancer treated with radiotherapy. Laryngoscope 1996;106:884–8.

    Article  Google Scholar 

  42. Krecicki T, Jelen M, Zalessaka-Krecicka M, et al. Epidermal growth factor receptor (EGFR), proliferating cell nuclear antigen (PCNA) and Ki-67 antigen in laryngeal epithelial lesions. Oral Oncol 1999;35:180–6.

    Article  CAS  Google Scholar 

  43. Hibi K, Trink B, Patturajan M, et al. AIS is an oncogen amplified in squamous cell carcinoma. Proc Natl Acad Sci USA 2000;97:5462–7.

    Article  CAS  Google Scholar 

  44. Celli J, Dujif P, Hamel B, et al. Heterozygous germline mutations in the p53 homologue p63 are the cause of EEC syndrome. Cell 1999;99:143–6.

    Article  CAS  Google Scholar 

  45. Zhong Z, Wen Z, Darnell JE. STAT3: A STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 1994;264:95–8.

    Article  CAS  Google Scholar 

  46. Grandis JR, Drenning SD, Zeng Q, et al. Constitutive activation of stat3 signaling abrogates apoptosis in squamous cell carcinogenesisin vivo. Proc Natl Acad Sci USA 2000;97:4227–32.

    Article  CAS  Google Scholar 

  47. Grandis JR, Zeng Q, Drenning SD. Epidermal growth factor receptor-mediated STAT3 signaling blocks apoptosis in head and neck cancer. Laryngoscope 2000;110:868–74.

    Article  CAS  Google Scholar 

  48. Chan G, Boyle JO, Yang EK, et al. Ciclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res 1999;59:991–1001.

    CAS  PubMed  Google Scholar 

  49. Lin DT, Subbaramaiah K, Shah JP, et al. Cycloxygenase-2: a novel molecular target for prevention and treatment of head and neck cancer. Head Neck 2002;24:792–9.

    Article  Google Scholar 

  50. Lane DP. Cancer, p53 guardian of the genome. Nature 1992;358:15–6.

    Article  CAS  Google Scholar 

  51. Boyle JO, Koch W, Ubran RH, et al. The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res 1993;53:4447–52.

    Google Scholar 

  52. Brenan JA, Boyle JO, Koch WM, et al. Association between cigarrettes smoking and mutation of p53 gene in head and neck squamous carcinoma. N Engl J Med 1995;332:712–9.

    Article  Google Scholar 

  53. Buckovich K, Duffy LA, Harlow E. The retionoblastoma protein is phosphorilated during specific phases of the cell cycle. Cell 1989;58:1097–105.

    Article  Google Scholar 

  54. Yoo GH, Xu HJ, Brennan JA, et al. Infrequent inactivation of the retinoblastome gene despite frequent loss of chromosome 13q in head and neck squamous cell carcinoma. Cancer Res 1994;54:4603–11.

    CAS  PubMed  Google Scholar 

  55. Dokiya F, Ueno K, Ma S, Eizuru Y, Furuta S, Ohyama M. Retinoblastoma protein expression and prognostic in laryngeal cancer. Acta Otolaryngol 1998;118:759–62.

    Article  CAS  Google Scholar 

  56. Pavelic ZP, Lasmar M, Pavelic L, et al. Absence of retinoblastoma gene product in human primary oral cavity carcinomas. Eur J Cancer Oral Oncol 1996;32B:347–515.

    Google Scholar 

  57. Gleich LL, Li YO, Biddinger PW, et al. The loss of heterozygosity in retinoblastoma and p53 supressor genes as a prognostic indicator for head and neck cancer. Laryngoscope 1996;106:1378–81.

    Article  Google Scholar 

  58. Lukas J, Parry D, Aagaard L, et al. Retinoblastoma-protein dependent cell-cycle inhibition by the tumor supressor p16. Nature 1995;375:503–6.

    Article  CAS  Google Scholar 

  59. Merlo A, Hernan JG, Mao L, et al. 5 CpG island metilation is associated with transcriptional silencing of the tumor supressor p16/CDKN2/MTS1 in human cancers. Nat Med 1995;7:686–91.

    Article  Google Scholar 

  60. Ogi K, Toyota M, Ohe-Toyota M, et al. Aberrant methylation in multiples genes and clinical-payhological features in oral squamous cell carcinoma. Cancer Res 2002;5:365–71.

    Google Scholar 

  61. Hussussiam CJ, Struewing JP, Goldstein AM, et al. Germline p16 mutations in familial melanoma. Nat Genet 1994;8:15–9.

    Article  Google Scholar 

  62. Bittencourt Rosas S, Koch W, Costa Caravaho M, et al. Promoter hypermethylation patterns of p16, O6 Methylguanina-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients. Cancer Res 2001;61:939–42.

    Google Scholar 

  63. Chen YJ, Chen PH, Lee MD, et al. Aberrantb FHIT transcripts in cancerous and corresponding non-cancerous lesions of the digestive tract. Int J Cancer 1997;72:955–60.

    Article  CAS  Google Scholar 

  64. Omacki K, Wu I, Riggins G, et al. Analysis of PTEN/MMACI alterations in aerodigestive tract tumors. Cancer Res 1998;58:509–12.

    Google Scholar 

  65. Tachibana M, Shibakita M, Ohno S, et al. Expression and prognostic significance of PTEN product protein in patients with esophageal squamous cell carcinoma. Cancer 2002;94:1955–60.

    Article  CAS  Google Scholar 

  66. Lee JI, Soria JC, Hassan KA, et al. Loss of PTEN expression as a prognostic marker for tongue cancer. Arch Otolaryngol Head Neck Surg 2001;127:1441–5.

    Article  CAS  Google Scholar 

  67. Kim SK, Fan Y, Papadimitrakopoulou V, et al. DPC4, a candidate supresor gen is altered infrequently in head and neck squamous cell carcinoma. Nat 1996;56:2516–20.

    Google Scholar 

  68. Garrigueantar L, Munozantonia T, Antonia SJ, et al. Missense mutations of the transforming growth factor beta type II receptor in human head and neck squamous cell squamous carcinoma cells. Cancer Res 1995;55:3982–9.

    CAS  Google Scholar 

  69. Lotan R, Xu XC, Lippman SM, et al. Supression of retinoic acid receptor beta in premalignant oral lesions and its up-regulation by isotretinoin. N Engl J Med 1995;332:1405–9.

    Article  CAS  Google Scholar 

  70. Park SH, Gray WC, Hernández I, et al. Phase I trial of alltrans retinoic acid in patients with treated head and neck squamous carcinoma. Clin Cancer Res 2000;6:847–54.

    CAS  PubMed  Google Scholar 

  71. Niles RM. Recent advances in the use of vitamin A (retinoids) in the prevention and tretment of cancer. Nutrition 2000;16:1084–9.

    Article  CAS  Google Scholar 

  72. Grandis JR, Falkner DM, Melhem MF, et al. Human leukocyte antigen class I allelic and haplotype loss in squamous cell carcinoma of the head and neck: clinical and inmunogenetic consequences. Clin Cancer Res 2000;6:2794–804.

    CAS  PubMed  Google Scholar 

  73. Sppaford MF, Koch WM, Reed AL, et al. Detection of head and neck squamous cell carcinoma among exfoliated oral mucosal cells by microsatellite analyses. Clin Cancer Res 2001;7:607–12.

    Google Scholar 

  74. Gostlich S, Foltz BJ, Goeroegh T, et al. A new prognostic indicator for head and neck cancer-p53 serum antibodies? Anticancer Res 1999;19:2703–5.

    Google Scholar 

  75. Ralha R, Nath N, Agarwal S, et al. Circulating p53 antibodies as early markers of oral cancer correlations with p53 alterations. Clin Cancer Res 1998;4:2147–52.

    Google Scholar 

  76. Belbin T, Signh B, Barber I, et al. Molecular classification of head and neck squamous cell carcinoma using cDNA microarrays. Cancer Res 2002;62:1184–90.

    CAS  PubMed  Google Scholar 

  77. Kim E, Kies M, Herbst R, et al. Novel therapeutics for head and neck cancer. Curr Opin Oncol 2002;3:334–42.

    Article  Google Scholar 

  78. Baselga J, Norton L, Massui H, et al. Antitumor effects of doxorrubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 1993;85:1327–33.

    Article  CAS  Google Scholar 

  79. Baselga J, Pfister D, Cooper MR, et al. Phase I studies of antiepidermal growth factor receptor chimeric antibody C225 in combination with cisplatin. J Clin Oncol 2000;18:904–14.

    Article  CAS  Google Scholar 

  80. Sirotnak FM, Zakowsky MF, Miller VA, Scher HI, Kris MG. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosin-kinase. Clin Cancer Res 2000;6:4885–92.

    CAS  PubMed  Google Scholar 

  81. Baselga J, Yano S, Giaccone G, et al. Initial results of a phase II trial of ZD1839 (Iressa) as second and third line monothjerapy for patients with non small cell lung cancer (IDEAL-1) [abstract]. Proceedings AACR-NCI-EORTC International conference 2001;630.

  82. Cohen EE, Rosen F, Satder WM, et al. Phase II trial of ZD1839 in recurrent of metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003;21:1980–7.

    Article  CAS  Google Scholar 

  83. Senzer NN, Soulieres D, Siu L, et al. Phase II evaluation of OSII-774 a potent oral antagonist of the EGFR-TK in patients with advanced squamous carcinoma of the head and neck [abstract]. Proc Am Soc Clin Oncol 2001;6.

  84. Zinner RG, Nemunaitis JJ, Donato NJ, et al. A phase I clinical and biomarker study of the novel pan-erbB tyrosin-kinase inhibitor, CI-1033 in patients with solid tumors [abstract]. Proc AARC-NCI-EORTC International conference 2001;566.

  85. Papadimitra-Kopoulou VA, Murren J, Fidler IJ, et al. A phase II dose escalating study to evaluate the biological activitty and pharmacokinetcs of PKI166, a novel tyrosine kinase inhibitor, in patients with advanced cancers [abstract]. Proc AACR-NCI-EORTC International Conference 2001;276.

  86. Lebowitz PF, Davide JP, Prendergast GC. Evidence that farnesyl transferase inhibitors supress Ras trasformation by interfering with Rho activity. Mol Cell Biol 1995;55:6613–22.

    Article  Google Scholar 

  87. Kim ES, Glisson BS, Meyers ML, et al. A phase I/II study of farnesyl transferase inhibitor (FTIs) SCH66336 (Ionafarnib) with paclitaxel in patients with solid tumors. Proc Am Cancer Res 2001;2629.

  88. Mackay HJ, Hoesktra R, Eskens F, et al. A phase I dose escalating study of BMS-214662 in combination with cisplatin in patients with advanced solid tumors [abstract]. Proc Am Soc Clin Oncol 2001;315.

  89. Nakagawa K, Yamamoto N, Nishio K, et al. A phase I, pharmacokinetc and pharmacodinamic study of farnesyltrasferase inhibitor (FTI) R115777 in japanese patients with advanced non haematological malignancies [abstract]. Proc Am Soc Clin Oncol 2001;317.

  90. Moasser MM, Sepp-Lorenzino, Kohl NE, et al. Farnesyl transferase inhibitors cause anhanced mitotic sensivity to taxol and epothilones. Proc Natl Acad Sci USA 1998;95:1369–74.

    Article  CAS  Google Scholar 

  91. Nemunaitis J, Khuri F, Ganly I, et al. Phase II trial of intratumoral administtration of ONYX-015, a replication selective adenovirus in patientes with refractory head and neck cancer. J Clin Oncol 2001;19:289–98.

    Article  CAS  Google Scholar 

  92. Khuri FR, Nemunaitis J, Ganly I, et al. A controlled trial of intratumoral ONYX-015, a sellectively-replicating adenovirus in combination with cisplatin and 5-fluoracil in patientes with recurrent head and neck cancer. Nat Med 2000;6:879–85.

    Article  CAS  Google Scholar 

  93. Ishida S, Yamashita T, Nakaya U, et al. Adenovirus mediated transfer of p53 related genes induces apoptosis of human cancer cells. Jpn J Cancer Res 2000;91:174–80.

    Article  CAS  Google Scholar 

  94. Clayman GL, El-Naggar AK, Nakaya U, et al. Adenovirus mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J Clin Oncol 1998;16:2221–32.

    Article  CAS  Google Scholar 

  95. Endo S, Zeng Q, Burke NA, et al. TGF-alpha antisense gene therapy inhibits head and neck squamous cell carcinoma growthin vivo. Gene Ther 2000;7:1906–14.

    Article  CAS  Google Scholar 

  96. Recchia F, Lalli A, Lombardo M, et al. Ifosfamide, cisplatin and 13-cis-retinoic acid for patients with advanced or recurrent squamous cell carcinoma of the head and neck: a phase I–II study. Cancer 2001;92:814–21.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Servicio de Oncología Médica, Hospital La Paz, Po de la Castellana, 261, 28046, Madrid, Spain

    María Sereno Moyano, Enrique Espinosa Arranz, Beatriz Castelo Fernández & Manuel González Barón

Authors
  1. María Sereno Moyano
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Enrique Espinosa Arranz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Beatriz Castelo Fernández
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Manuel González Barón
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Moyano, M.S., Arranz, E.E., Fernández, B.C. et al. Biología Molecular de los cánceres de cabeza y cuello. Rev Oncol 5, 500–510 (2003). https://doi.org/10.1007/BF02710397

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02710397

Palabras clave

Key words

Search

Navigation